Inhibition of Lactation with Quinestrol

Barbour, Edward M.; Baruah, N. K.

doi:10.1177/003693306801300805

Cited by 10 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other workers (Barbour and Baruah, 1968;Kuku, 1968;McGlone, 1969;and Watson, 1969) investigated the effect of quinestrol, a longacting oestrogen, in suppressing lactation. This SUbstance was compared with stilboestrol and a placebo and the reports were unanimous in finding quinestrol the more successful.…”

Section: Introductionmentioning

confidence: 99%

A Combined/Oestrogen/Progestogen/Testosterone Agent for the Inhibition of Lactation

E¹,

Jo²

1972

Int J Clinical Practice

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

A Combined/Oestrogen/Progestogen/Testosterone Agent for the Inhibition of Lactation

E¹,

Jo²

1972

Int J Clinical Practice

View full text Add to dashboard Cite

“…More recently, quinestrol, the 3-cyclopentyl ether of ethinyl oestradiol, has been used to inhibit lactation (Barbour and Baruah, 1968). This oestrogen is long acting because it is absorbed into body fat depots and then slowly released (Cohen et al, 1966).…”

mentioning

confidence: 99%

The Effects of Stilboestrol and Quinestrol Upon Coagulation and Fibrinolysis During the Puerperium

Howie¹,

Evans²,

Forbes³

et al. 1976

Obstetrical & Gynecological Survey

View full text Add to dashboard Cite

Two oestrogens, stilboestrol and quinestrol, were used to inhibit lactation and their effects upon coagulation and fibrinolysis were compared with control patients before delivery, during the puerperium and six weeks after delivery. During the first week of the puerperium, stilboestrol therapy was associated with rises of factors IX and X and quinestrol therapy with rises of factors IX and 11. Six weeks after delivery, the clotting factors were similar to the control values in those who had received stilboestrol but factor I1 was still raised in the quinestrol treated patients. Additionally, a significant rise of factor X in the quinestrol group was noted at this time. Plasma antithrombin levels rose during the first week of the puerperium in all three groups but, six weeks after delivery, they were lower in those who had received oestrogens. Stilboestrol and quinestrol were also associated with a rise of plasminogen and antiplasmin concentration during the first week of the puerperium. Six weeks after delivery, quinestrol treated patients still had raised levels of plasminogen and antiplasmin while the stilboestrol treated patients only had raised levels of antiplasmin. These changes in coagulation and fibrinolysis are similar to those reported during oral contraceptive therapy. The persisting changes six weeks after delivery in women who had taken quinestrol might indicate an increased thrombogenic risk when long acting oestrogen preparations are used to inhibit lactation.

show abstract

“…In recent comparative trials the relative failure rates (failure having been defined as a patient in whom further suppressional treatment has been required in addition to the drug of routine choice) have been shown to be hexoestrol 20% (Firth, 1969), ethinyl oestradiol 37% (Kuku, 1968) and stilboestrol 58% (Barbour and Baruah, 1968).…”

mentioning

confidence: 99%

A Comparative Study of Two Fat‐stored Oestrogens in Inhibiting Lactation

King

1972

Int J Clinical Practice

View full text Add to dashboard Cite

Inhibition of Lactation with Quinestrol

Abstract: A new synthetic oestrogen is shown to have a highly significant advantage over standard therapy in the inhibition of lactation.

Cited by 10 publications

References 2 publications

A Combined/Oestrogen/Progestogen/Testosterone Agent for the Inhibition of Lactation

A Combined/Oestrogen/Progestogen/Testosterone Agent for the Inhibition of Lactation

The Effects of Stilboestrol and Quinestrol Upon Coagulation and Fibrinolysis During the Puerperium

A Comparative Study of Two Fat‐stored Oestrogens in Inhibiting Lactation

Contact Info

Product

Resources

About